In a big week for Ebola vaccines, Emergent Biosciences and GlaxoSmithKline have begun a Phase I trial of their candidates, while Bavarian Nordic received €50 million ($56 million) in loans from the European Investment Bank that go in part toward its programs in Ebola and infectious diseases.
In a $31 million development agreement with Emergent BioSolutions announced Monday, the Department of Health and Human Services said it will fund Phase III development for NuThrax, Emergent's new anthrax vaccine that's already been funded through Phase I and II by the NIH and the Department of Defense.
Maryland's Emergent BioSolutions won FDA approval for an injected treatment for anthrax infection, padding the company's stable of biodefense products.
GlaxoSmithKline is testing its Ebola jab in Africa to see if it provokes an immune response strong enough to successfully beat an Ebola infection. But if it turns out to be too weak, never fear--the Big Pharma has a plan. It's teaming up with Maryland-based Emergent BioSolutions to test the latter's Ebola shot as a booster for its own vaccine.
German drug developer MorphoSys is pairing up with Emergent BioSolutions to get its hands on an early-stage prostate cancer treatment, signing a deal worth up to $183 million for a promising antibody.
Emergent BioSolutions, already the go-to company for anthrax vaccines, will buy Cangene Corp. for about $222 million, adding to its stable of biodefense contracts and picking up a contract manufacturing business that can kick in some additional revenue.
The FDA has lifted the clinical hold on PharmAthene's anthrax vaccine candidate, SparVax.
Emergent BioSolutions snagged the exclusive right to manufacture and sell VaxInnate's flu vaccine, a product Emergent can produce quickly at high yields and low cost.
University of Cape Town's South African Tuberculosis Vaccine Initiative and Stellenbosch's Desmond Tutu TB Centre are recruiting infants to test a new tuberculosis vaccine for newborns of HIV-positive moms, a demographic not served by the current vaccine.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...